Clinical trials
Recurrent Nasopharyngeal Carcinoma clinical trials
Below are recruiting recurrent nasopharyngeal carcinoma clinical trials, each written for real people, not researchers. We’re tracking 66 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04136886RecruitingPhase 3
Chemo trial for return of advanced nasopharyngeal cancer
This Phase 3 study tests a chemotherapy plan for people whose nasopharyngeal cancer has come back locally (T3/T4). It aims to see if treatment given after return of cancer can help control the disease without spreading to distant organs.
Guangzhou, GuangdongAges 18–70 - NCT04453813RecruitingPhase 3
Immunotherapy with chemoradiation for recurring nasopharyngeal cancer
This phase 3 trial tests whether adding toripalimab (an immunotherapy medicine) to standard chemo-radiation works better for treating nasopharyngeal cancer that has come back and cannot be removed by surgery. It aims to improve control of the cancer after it returns.
Guangzhou, GuangdongAges 18–70 - NCT04448522RecruitingPhase 3
Lower-dose radiotherapy for EBV-responsive nasopharyngeal cancer
This Phase 3 study tests whether giving a reduced amount of radiotherapy can work as well as the standard dose for certain people with stage II–III nasopharyngeal cancer who respond well after initial chemotherapy. It’s designed for patients whose cancer markers improve after 3 chemotherapy cycles, to potentially reduce treatment side effects while keeping cancer control.
Guangzhou, GuangdongAges 18–70 - NCT04778956RecruitingPhase 3
Toripalimab plus surgery vs surgery alone for recurring throat cancer
This trial tests whether adding toripalimab (an immune therapy) to surgery helps people with recurrent nasopharyngeal cancer live longer or control the cancer better than surgery alone. You may qualify if your recurrence can be fully removed by surgery and it came back after a certain amount of time.
Guangzhou, GuangdongAges 18–70 - NCT04376866RecruitingPhase 3
Immunotherapy for repeat nasopharyngeal cancer after it returns
This trial studies toripalimab (an immunotherapy that helps your immune system attack cancer) for nasopharyngeal cancer that has come back locally. It may help shrink or control the returning tumor and improve outcomes for people who meet the safety and lab requirements.
Nanning, GuangxiAges 18–65 - NCT05352321Recruiting
Surgery plus targeted chemoradiation versus standard chemoradiation
This trial compares two treatment plans for newly diagnosed, operable nasopharyngeal cancer: adding surgery plus targeted chemoradiation versus standard chemoradiation alone. It aims to see whether the surgery-based plan improves control of the cancer and related outcomes.
Guangzhou, GuangdongAges 18–70 - NCT05877872RecruitingPhase 3
Smaller surgery after chemotherapy for recurring nasopharyngeal cancer
This trial tests whether doing a smaller surgery (after chemotherapy works well) can control recurring nasopharyngeal cancer while reducing treatment burden. It is for people whose cancer can be removed by surgery and who respond to an initial course of chemotherapy plus immunotherapy (or another targeted regimen).
Guangzhou, GuangdongAges 18–75 - NCT06241599RecruitingPhase 2/Phase 3
AK104 with chemo for advanced nasopharyngeal cancer
This study tests if adding a new immunotherapy drug (called AK104) to standard chemotherapy can help people whose nasopharyngeal cancer has come back or spread after previous treatment. The goal is to see if the combination works better than chemotherapy alone.
Guangzhou, GuangdongAges 18–75 - NCT06019130RecruitingPhase 2
Nivolumab for newly diagnosed nasopharyngeal cancer
This trial tests whether the immunotherapy drug nivolumab (Opdivo) can help treat nasopharyngeal cancer in both children and adults. It is for people who have just been diagnosed and have not yet received any cancer treatment.
AachenAges 3 years+ - NCT06455410RecruitingPhase 2
GP plus adebrelimab vs. chemo alone for nasopharyngeal cancer
This trial tests a new combination of chemotherapy drugs (GP) plus an immunotherapy drug (adebrelimab) before standard treatment for nasopharyngeal cancer. It aims to see if this combination works better than chemotherapy alone for shrinking tumors.
Foshan, GuangdongAges 18–65 - NCT06529562Recruiting
Surgery plus reduced chemo and radiation vs standard for nasopharyngeal cancer
This trial compares two approaches for people with early-stage nasopharyngeal cancer that can be removed with surgery. It tests whether giving less intense chemotherapy and radiation after surgery works as well as a standard dose, with fewer side effects.
Zhuhai, GuangdongAges 18–70 - NCT06533267Recruiting
Endoscopic surgery vs. radiation for early-stage nasal cancer
This trial compares two treatments for stage I nasopharyngeal cancer (a type of nasal cancer). It tests whether a minimally invasive surgery (endoscopic surgery) is as good as or better than radiation therapy. It may be an option for people whose cancer is small and hasn't spread to lymph nodes.
Zhuhai, GuangdongAges 18–75 - NCT07781358RecruitingPhase 2
Testing a new drug combination for recurrent nasopharyngeal cancer
This trial tests a new drug combination for people whose nasopharyngeal cancer has come back in the same area or nearby lymph nodes. The goal is to see if this treatment can shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT07705243RecruitingPhase 3
Maintenance therapy for advanced nasopharyngeal cancer
This trial tests a combination of two drugs (becotatug vedotin and an anti-PD1 immunotherapy) as maintenance treatment after initial chemotherapy for advanced nasopharyngeal cancer that has spread or returned. It's for people whose disease has not progressed after standard first-line treatment.
Guangzhou, GuangdongAges 18–75 - NCT06688760Recruiting
Surgery vs surgery plus lower-dose radiation for early nasopharyngeal cancer
This trial compares two treatments for newly diagnosed Stage I nasopharyngeal cancer: surgery alone versus surgery followed by a lower dose of radiation. The goal is to see if adding a gentler radiation dose can prevent the cancer from coming back without too many side effects.
Guangzhou, GuangdongAges 18–70 - NCT07581821RecruitingPhase 2
Immunotherapy plus targeted drugs for advanced nasopharyngeal cancer
This trial tests a combination of three drugs (sintilimab, anlotinib, and chemotherapy) for nasopharyngeal cancer that has returned or spread after initial treatment. The goal is to see if this combination helps slow or shrink the cancer.
Zhuhai, GuangdongAges 18–65 - NCT07528183RecruitingPhase 2
Immunotherapy after chemo and radiation for recurrent nose cancer
This trial tests whether maintenance immunotherapy (PD-1 inhibitor) followed by delayed salvage radiation therapy can help keep your cancer under control after you have already responded to initial chemo-immunotherapy. It is for people with recurrent nasopharyngeal carcinoma that has come back in the nose or neck area, but has not spread to distant organs.
Fuzhou, FujianAges 18–70 - NCT07412314Recruiting
Proton Therapy for Recurrent Nasopharyngeal Cancer
This trial uses proton therapy (a precise type of radiation) to treat people whose nasopharyngeal cancer has come back. It aims to see if this treatment can help control the cancer while limiting side effects.
Guangzhou, GuangdongAges 18 years+ - NCT06851247RecruitingPhase 2
Chemoradiation plus toripalimab for advanced nasopharyngeal cancer
This trial tests a new treatment for advanced nasopharyngeal cancer. You will get chemotherapy and radiation, followed by maintenance therapy with an immunotherapy drug called toripalimab to help your immune system fight the cancer.
Guangzhou, GuangdongAges 18–65 - NCT07277764RecruitingPhase 2
Radiation and immunotherapy for returning nasopharyngeal cancer
This trial tests a combination of high and low dose radiation plus an immunotherapy drug (PD-1 inhibitor) for people whose nasopharyngeal cancer has come back after previous treatment. The goal is to see if this approach can be more effective while reducing side effects.
Nanchang, JiangxiAges 18–75 - NCT07258979RecruitingPhase 1/Phase 2
YL201 and Toripalimab with or without Cisplatin for Nasopharyngeal Cancer
This trial tests a new drug combination for people with advanced or recurrent nasopharyngeal cancer. It aims to see if YL201 plus Toripalimab (and sometimes cisplatin) can help when standard treatments are not an option.
Chongqing, Chongqing MunicipalityAges 18–75 - NCT06912711RecruitingPhase 2
Chemo before and after surgery for recurrent nasal cancer
This trial tests giving chemotherapy before and after surgery for people whose nasal cancer has come back. The goal is to see if this approach helps remove the cancer more effectively and prevents it from returning again.
Guangzhou, GuangdongAges 18–65 - NCT07070479RecruitingPhase 2
Combination treatment for PD-1 resistant nasopharyngeal cancer
This trial is testing a combination of drugs for people whose nasopharyngeal cancer has stopped responding to standard treatments like platinum chemotherapy and PD-1 inhibitors. It aims to find a new effective approach for advanced or recurrent disease.
Guangzhou, GuangdongAges 18–70 - NCT06235203RecruitingPhase 3
Comparing treatment timing in recurrent nasopharyngeal cancer
This trial compares giving chemotherapy and immunotherapy before surgery (neoadjuvant) versus after surgery (adjuvant) for patients whose nasopharyngeal cancer has returned locally. It aims to find which approach works better to control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Recurrent Nasopharyngeal Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for recurrent nasopharyngeal carcinoma?
- Yes. Clin2 currently lists 66 recruiting recurrent nasopharyngeal carcinoma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a recurrent nasopharyngeal carcinoma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a recurrent nasopharyngeal carcinoma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.